European Commission Approves Tablet Formulation of BeOne Medicines’ BRUKINSA® for All Approved Indications

Contributed by: Business Wire

Logo

Tags

Biotechnology

Health

Pharmaceutical

Clinical Trials

Oncology

EC BRUKINSA Tablet Approval

More Like This

U.S. FDA Approves Tablet Formulation of BeOne’s BRUKINSA® for All Approved Indications

BeOne Medicines Receives Positive CHMP Opinion for Tablet Formulation of BRUKINSA®

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 2026

BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025

BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit

BeOne Medicines Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare Conference

BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 2025

BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 2025